Artemisinin is a drug used to treat multi-drug resistant strains of falciparum malaria. The compound (a sesquiterpene lactone) is isolated from the plant Artemisia annua. Not all plants of this species contain artemisinin.
The National Institutes of Health has renewed a major grant that funds a University of Washington-led research center to understand malaria in India.
Malaria is more common and severe in pregnant women, increasing their risk of miscarriage and other adverse outcomes. The adverse consequences of malaria in pregnancy require prompt, safe, and effective treatment.
When the standard malaria medications failed to help 18 critically ill patients, the attending physician in a Congo clinic acted under the "compassionate use" doctrine and prescribed a not-yet-approved malaria therapy made only from the dried leaves of the Artemisia annua plant.
Since the ancient times, mankind has used plants to treat diseases. An example is the plant Artemisia annua, used for over 2,000 years in traditional Chinese medicine to treat intermittent fevers.
Researchers at Cardiff University have devised a new way of creating a drug commonly used as the first line of defence against malaria around the world.
Malaria infections may soon be treated much more efficiently than they are at present. Researchers at the Universities of Bayreuth and Jerusalem have developed a novel drug release procedure for this purpose.
The iron-containing molecule heme is necessary for life. Cells require heme to perform the chemical reactions that produce energy, among other critical tasks.
A centuries-old herbal medicine, discovered by Chinese scientists and used to effectively treat malaria, has been found to potentially aid in the treatment of tuberculosis and may slow the evolution of drug resistance.
The Monell Center announced today that it has received a $345,000 grant from the Bill & Melinda Gates Foundation. The grant supports an innovative global health research project titled, "Developing Novel Pediatric Formulation Technologies for Global Health: Human Taste Assays."
Malaria is one of the leading causes of mortality in developing countries – last year killing more than 400,000 people. Researchers worldwide have found the solution for drug discovery could lie in open, “crowd-sourced” science.
Malaria remains one of the world's leading causes of mortality in developing countries. Last year alone, it killed more than 400,000 people, mostly young children.
For chemists like Sarah Reisman, professor of chemistry at Caltech, synthesizing molecules is like designing your own jigsaw puzzle. You know what the solved puzzle looks like--the molecule--and your job is to figure out the best pieces to use to put it together.
Malaria researchers at The Australian National University have found one of the malaria parasite's best weapons against drug treatments turns out to be an Achilles' heel, which could be exploited to cure the deadly disease.
Researchers, led by Carnegie Mellon University President Subra Suresh and MIT Principal Research Scientist Ming Dao, have created a new computer model that shows how tiny slits in the spleen prevent old, diseased or misshapen red blood cells from re-entering the bloodstream.
The first global mapping of artemisinin resistance has definitively confirmed that resistance to the main drug currently used in the treatment of Plasmodium falciparum malaria is for the moment confined to Southeast Asia and has not spread to sub-Saharan Africa.
A new and inexpensive technique for mass-producing the main ingredient in the most effective treatment for malaria, artemisinin, could help meet global demands for the drug, according to a study to be published in the journal eLife.
A combination of artemisinin and another drug (artemisinin combination therapy, ACT) is currently the best malaria treatment recommended by the World Health Organization.
New research led by Professor Cathie Martin of the John Innes Centre has revealed how a plant used in traditional Chinese medicine produces compounds which may help to treat cancer and liver diseases.
In order to preserve first-line drugs for treating malaria, multiple combination therapies should be deployed within a population to prevent resistance from developing, according to Maciej Boni from the Centre for Tropical Medicine and Global Health, University of Oxford, UK, and colleagues in a Policy Forum article published in this week's PLOS Medicine.
Scientists have documented for the first time how competition among different malaria parasite strains in human hosts could influence the spread of drug resistance.